- Home
- CHNR vs RDHL Comparison
CHNR vs RDHL Comparison
Compare CHNR & RDHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CHNR
- RDHL
- Stock Information
- Founded
- CHNR N/A
- RDHL 2009
- Country
- CHNR China
- RDHL Israel
- Employees
- CHNR N/A
- RDHL N/A
- Industry
- CHNR Precious Metals
- RDHL Biotechnology: Pharmaceutical Preparations
- Sector
- CHNR Basic Materials
- RDHL Health Care
- Exchange
- CHNR Nasdaq
- RDHL Nasdaq
- Market Cap
- CHNR 4.7M
- RDHL 3.9M
- IPO Year
- CHNR 1995
- RDHL N/A
- Fundamental
- Price
- CHNR $3.32
- RDHL $1.07
- Analyst Decision
- CHNR
- RDHL
- Analyst Count
- CHNR 0
- RDHL 0
- Target Price
- CHNR N/A
- RDHL N/A
- AVG Volume (30 Days)
- CHNR 18.6K
- RDHL 1.5M
- Earning Date
- CHNR 12-12-2025
- RDHL 09-05-2025
- Dividend Yield
- CHNR N/A
- RDHL N/A
- EPS Growth
- CHNR N/A
- RDHL N/A
- EPS
- CHNR N/A
- RDHL N/A
- Revenue
- CHNR N/A
- RDHL $9,550,000.00
- Revenue This Year
- CHNR N/A
- RDHL $381.91
- Revenue Next Year
- CHNR N/A
- RDHL N/A
- P/E Ratio
- CHNR N/A
- RDHL N/A
- Revenue Growth
- CHNR N/A
- RDHL 157.62
- 52 Week Low
- CHNR $3.16
- RDHL $1.01
- 52 Week High
- CHNR $8.20
- RDHL $8.75
- Technical
- Relative Strength Index (RSI)
- CHNR 25.25
- RDHL 33.14
- Support Level
- CHNR $3.21
- RDHL $1.01
- Resistance Level
- CHNR $3.84
- RDHL $1.07
- Average True Range (ATR)
- CHNR 0.25
- RDHL 0.09
- MACD
- CHNR -0.09
- RDHL 0.01
- Stochastic Oscillator
- CHNR 10.00
- RDHL 5.26
About CHNR China Natural Resources Inc.
China Natural Resources Inc is engaged in exploration for lead, silver, and other metals in the Inner Mongolia Autonomous Region of the PRC and exploration of attractive opportunities in other sectors. The company has a single operating segment: exploration and mining.
About RDHL Redhill Biopharma Ltd.
Redhill Biopharma Ltd is a specialty biopharmaceutical company focused on gastrointestinal diseases. The company is dedicated to advancing its development pipeline of clinical-stage therapeutic candidates. It also commercializes GI-related products in the U.S., including Talicia (omeprazole, amoxicillin, and rifabutin) and Aemcolo (rifamycin). Currently, the company's pipeline consists of five therapeutic candidates: Opaganib, RHB-107, RHB-102, RHB-204, and RHB-104, the majority of which are in clinical development.